Cannabis Vaping and Smoking Trigger the Same Inflammatory and Cancer Gene Pathways in Lung Cells

Comparison of cannabis smoke extract (CaSE) and cannabis vape extract (CaVE) using: chemical analysis (HPLC and GC/MS), BRET-based biosensor for receptor-mediated activity, RNA sequencing for transcriptomic changes, and targeted metabolomics — all in human bronchial epithelial cells. Assessed inflammatory pathways, cancer-related gene expression, cellular stress responses, and metabolite changes.

The cannabis industry and many public health messages position vaping as harm reduction. This study suggests that at the cellular level, the harm reduction may be more limited than assumed. If the inflammatory, cancer, and stress pathways activated by vaping are the same as those activated by smoking, the long-term health consequences may converge even if the acute chemical exposure differs.

This directly challenges the vaping harm reduction narrative from RTHC-00110 (lung health review) and complicates RTHC-00122 (route-specific effects). While gross chemical exposure is lower with vaping, this cellular-level study suggests the biological damage pathways are similar. Combined with RTHC-00128 (comparable respiratory symptoms from cannabis and nicotine vaping), the evidence is building that cannabis vaping isn't as safe as commonly perceived — at least for the lungs.

In vitro study — cell culture exposure doesn't replicate the complex dynamics of actual lungs (airway clearance, immune response, tissue repair). The concentrations of CaSE and CaVE used on cells may not reflect real-world exposure levels. Single cell type (bronchial epithelium) doesn't capture the full respiratory tract response. Acute exposure only — chronic effects of repeated low-level vaping exposure aren't addressed. The specific cannabis products and vaping devices used may not represent the full market.